One Pager as on February 28, 2023
|Optimal asset allocation at regular intervals.|
|Aims to capture the optimum mix between Equity and Debt across market cycles.|
|With flexibility to invest upto 100% in equity & debt, the Scheme may be suitable for volatile market conditions.|
|Endeavours to provide tax efficiency*|
*Though the scheme is a dynamic asset allocation scheme, the endeavour will be to invest a minimum of 65% of its net assets in equity and equity related instruments which may help in attracting equity taxation as per prevailing tax laws.
|Sector||MMBAF||Nifty 50 Hybrid Composite Debt 50: 50 Index TRI|
Data as on February 28, 2023
|Security||% to Net Assets|
|HDFC Bank Limited||6.45%|
|Tech Mahindra Limited||3.81%|
|Reliance Industries Limited||3.09%|
|Ambuja Cements Limited||2.60%|
|ICICI Bank Limited||2.32%|
|Sun Pharmaceutical Industries Limited||2.19%|
|IndusInd Bank Limited||2.00%|
|State Bank of India||1.83%|
|Fresh Additions||Complete Exits|
|Abbott India Limited||City Union Bank Limited|
|Jindal Stainless (Hisar) Limited||Hindustan Aeronautics Limited|
|Max Financial Services Limited||Kotak Mahindra Bank Limited|
|Tata Power Company Limited|
Note: The companies/stock(s) referred above are only for the purpose of disclosure of significant portfolio changes during the month and should not be construed as recommendation to buy/sell/ hold. The fund manager may or may not choose to hold these companies/stocks, from time to time. Investors are requested to consult their financial, tax and other advisors before taking any investment decision(s). Data as on February 28, 2023
|Annualised Portfolio YTM*1^||7.42%2|
|Macaulay Duration^||2.62 years2|
|Residual Maturity^||3.24 years2|
*In case of semi annual YTM, it will be annualised
^For debt component
1Yield to maturity should not be construed as minimum return offered by the Scheme;
2Calculated on amount invested in debt securities (including accrued interest), deployment of funds in TREPS and Reverse Repo and net receivable / payable. Data as on February 28, 2023
^Benchmark ^^Additional Benchmark. Inception/Allotment date: 30-Dec-21.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. Since inception returns of the scheme is calculated on face value of Rs. 10 invested at inception. The performance details provided above are of Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. *Based on standard investment of Rs. 10,000 made at the beginning of the relevant period.
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 30-December-21.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. Returns greater than 1 year period are compounded annualized. For SIP returns, monthly investment of equal amounts invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).
^Benchmark CAGR – Compounded Annual Growth Rate. $Dedicated Fund Manager for Overseas Investments.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. The performance details provided above are of Growth Option under Regular Plan Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Mr. Rahul Pal manages 10 schemes, Mr. Manish Lodha manages 10 schemes and Ms. Fatema Pacha manages 9 schemes each of Mahindra Manulife Mutual Fund. The performance data for the schemes which have not completed one year has not been provided.
This product is suitable for investors who are seeking*:
• Capital Appreciation while generating income over medium to long term;
• Investments in a dynamically managed portfolio of equity and equity related instruments and debt and money market instruments.
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.